Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
- Conditions
- Leukemia
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00002609
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
- Conditions
- Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: FilgrastimDrug: CladribineDrug: CyclosporineDrug: Cytarabine (Ara-C)Drug: Fludarabine PhosphateDrug: IdarubicinDrug: MethylprednisoloneProcedure: Peripheral Blood Stem Cell Transplantation
- First Posted Date
- 2004-07-30
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00002833
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 1520
- Registration Number
- NCT00002549
- Locations
- 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Scotland and Newcastle Lymphoma Group
- Target Recruit Count
- 200
- Registration Number
- NCT00003639
- Locations
- 🇬🇧
Royal Victoria Infirmary, Newcastle-upon-Tyne, England, United Kingdom
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00002565
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇧🇷Faculdade de Medicina do ABC, Sao Paulo, Brazil
🇨🇱Clinica Alemana, Santiago, Chile
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: cytarabineDrug: dexamethasoneDrug: etoposideDrug: idarubicinDrug: ifosfamideDrug: leucovorin calciumDrug: mesnaDrug: pegaspargaseDrug: therapeutic hydrocortisoneDrug: thioguanineDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapyDrug: Methotrexate
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT00002816
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Kaplan Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 60
- Registration Number
- NCT00003758
- Locations
- 🇮🇹
Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, Italy
🇳🇱Groot Ziekengasthuis 's-Hertogenbosch, 's-Hertogenbosch, Netherlands
🇳🇱Sint Joseph Ziekenhuis, Veldhoven, Netherlands
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Rush University Medical Center
- Registration Number
- NCT00003405
- Locations
- 🇺🇸
Rush-Riverside Cancer Center, Kankakee, Illinois, United States
🇺🇸Cook County Hospital, Chicago, Illinois, United States
🇺🇸Rush Cancer Institute, Chicago, Illinois, United States
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- LeukemiaNeutropenia
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 500
- Registration Number
- NCT00002719
- Locations
- 🇮🇹
Azienda Policlinico Umberto Primo, Rome, Italy
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
- Conditions
- Graft Versus Host DiseaseLeukemia
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004878
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.